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Viral infection activates transcription factors NF-kB
and IRF3, which collaborate to induce type I inter-
ferons (IFNs) and elicit innate antiviral response.
MITA (also known as STING) has recently been
identified as an adaptor that links virus-sensing
receptors to IRF3 activation. Here, we showed that
the E3 ubiquitin ligase RNF5 interacted with MITA in
a viral-infection-dependent manner. Overexpression
of RNF5 inhibited virus-triggered IRF3 activation,
IFNB1 expression, and cellular antiviral response,
whereas knockdown of RNF5 had opposite effects.
RNF5 targeted MITA at Lys150 for ubiquitination
and degradation after viral infection. Both MITA and
RNF5 were located at the mitochondria and endo-
plasmic reticulum (ER) and viral infection caused their
redistribution to the ER and mitochondria, respec-
tively.We further found that virus-induced ubiquitina-
tionanddegradationofMITAbyRNF5occurredat the
mitochondria. These findings suggest that RNF5
negatively regulates virus-triggered signaling by
targeting MITA for ubiquitination and degradation at
the mitochondria.
INTRODUCTION
Viral infection triggers a series of signaling events that lead to
induction of type I interferons (IFNs). Type I IFNs activate the
JAK-STAT signal transduction pathways, leading to transcrip-
tional induction of a wide range of downstream antiviral genes
and subsequent innate antiviral response (Akira et al., 2006;
Durbin et al., 2000; Hiscott, 2007; Honda et al., 2006). Transcrip-
tional induction of type I IFN genes requires the coordinate
activation of multiple transcription factors and their cooperative
assembly into transcriptional enhancer complexes in vivo. For
example, the IFNB1 gene promoter contains conserved
enhancer elements recognized by NF-kB (kB site) and phos-
phorylated IRF3 (ISRE site, also known as PRDIII or IRF-E). It
has been shown that transcriptional activation of the IFNB1
gene requires coordinate and cooperative assembly of anenhanceosome that contains all of these transcription factors
(Honda et al., 2006; Maniatis et al., 1998).
At least two types of viral-sensing receptors are capable of
triggering signaling events leading to induction of type I IFNs.
One is mediated by Toll-like receptors (TLRs). For example,
engagement of TLR3 by dsRNA triggers TLR-interacting factor
(TRIF)-mediated induction of type I IFNs (O’Neill and Bowie,
2007; Oshiumi et al., 2003; Yamamoto et al., 2003). The second
mechanism involves two RIG-I-like receptors (RLRs), RIG-I and
MDA5, which function as cytoplasmic viral RNA sensors
(Hornung et al., 2006; Kato et al., 2006; Pichlmair et al., 2006;
Yoneyama et al., 2004). Both RIG-I and MDA5 contain two
CARD modules at their N terminus and a DexD/H-box RNA
helicase domain at their C terminus. The RNA helicase domains
of RIG-I and MDA5 serve as intracellular viral RNA receptors,
whereas the CARD modules are responsible for transmitting
signals to downstream CARD-containing mitochondrion-located
adaptor protein VISA (also known as MAVS, IPS-1, and Cardif)
(Kawai et al., 2005; Meylan et al., 2005; Seth et al., 2005; Sun
et al., 2006; Xu et al., 2005). The adaptor protein VISA further
activates the IKK-protein-kinase family members. Although the
canonical IKK family members IKKa and IKKb are essential for
virus-triggered NF-kB activation, the noncanonical IKK family
members TBK1 and IKK3 are responsible for phosphorylating
and activating IRF3 and IRF7 (Fitzgerald et al., 2003; Hemmi
et al., 2004; Matsui et al., 2006). Various studies have also
demonstrated the involvement of several other signaling compo-
nents in virus-induced activation of NF-kB and/or IRF3, including
TRAF3, TRAF6, TANK, NEMO(IKKg), TRADD, FADD, and RIP
(Kawai et al., 2005; Michallet et al., 2008; Oganesyan et al.,
2006; Saha et al., 2006; Xu et al., 2005; Zhao et al., 2007).
Recently, we and others identified a new adaptor protein
called MITA (or STING), which plays a critical role in virus-
induced type I IFN expression (Ishikawa and Barber, 2008;
Zhong et al., 2008). Overexpression of MITA activates IRF3,
whereas knockdown or deletion of MITA inhibits virus-triggered
and VISA-mediated IRF3 activation, induction of type I IFNs, and
cellular antiviral response. MITA is found to localize to the outer
membrane of mitochondria (Jin et al., 2008; Zhong et al., 2008) or
the endoplasmic reticulum (ER) (Ishikawa and Barber, 2008). It
has been demonstrated that MITA acts as an adaptor to recruit
TBK1 and IRF3 to the VISA-associated complex after viral infec-
tion (Zhong et al., 2008).Immunity 30, 397–407, March 20, 2009 ª2009 Elsevier Inc. 397
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(A) A schematic presentation of full-length RNF5,
MITA and their mutants. RING, ring-finger domain;
TM, transmembrane domain.
(B) RNF5 interacts with MITA through its trans-
membrane domain. 293 cells (23 106) were trans-
fected with the indicated plasmids (5 mg each).
Coimmunoprecipitations were performed with
anti-Flag or control IgG. Immunoblot analysis
was performed with anti-HA (upper panel).
Expression of the proteins were analyzed by
immunoblot analysis of the lysates with anti-HA
and anti-Flag (lower panels).
(C) MITA is associated with RNF5 through its third
transmembrane domain. Experiments were per-
formed similarly as in (B).
(D) Effect of viral infection on endogenous MITA-
RNF5 interaction. 293 cells (53 107) were left unin-
fected or infected with SeV for 6 hr. The cells were
lysed and the lysates were immunoprecipitated
with anti-RNF5 or control serum. The immunopre-
cipitates were analyzed by immunoblotting with
anti-MITA (upper panel). The expression levels of
the endogenous proteins were detected by immu-
noblot analysis with anti-MITA and anti-RNF5
(lower panels). For (B)–(D), the experiments were
performed for three times with similar results.In this report, we found that the E3 ubiquitin ligase ring finger
protein 5 (RNF5, also called RMA1) (Kyushiki et al., 1997;
Matsuda et al., 2001) interacted with and ubiquitinated MITA
after viral infection. Ubiquitination of MITA by RNF5 led to its
degradation and inhibition of virus-induced IRF3 activation,
IFNB1 expression, and cellular antiviral response. Our findings
identified a new strategy for host cells to control excessive innate
immune response after viral infection.
RESULTS
Identification of RNF5 as a MITA-Interacting Protein
Previous studies have shown that MITA plays a critical role in
virus-induced IRF3 activation and type I IFN induction (Ishikawa
and Barber, 2008; Zhong et al., 2008). To investigate how MITA is
regulated in virus-induced signaling events, we attempted to
identify MITA-interacting proteins by yeast two-hybrid screens.
Using full-length MITA as bait, we screened 2 3 106 indepen-
dent clones from a combination of human 293 and B cell cDNA
libraries and obtained 35 b-gal positive clones. Sequencing
analysis and blast searches of the GenBank databases indicated
that two of these clones encoded full-length RNF5 or its
C-terminal region (aa 21180).
RNF5 is an E3 ubiquitin ligase that has been implicated in cell
motility, protein quality control in the ER, cancer, and degenera-
tive myopathy (Bromberg et al., 2007; Didier et al., 2003;
Younger et al., 2006). It has been shown that RNF5 contains
a transmembrane domain at its C terminus and is localized to
the ER (Younger et al., 2006). Because MITA has been shown
to localize at the mitochondria and ER (Ishikawa and Barber,
2008; Zhong et al., 2008), we investigated whether MITA
physically interacts with RNF5 in mammalian cells. In transient
transfection and coimmunoprecipitation experiments, RNF5
interacted with MITA. Deletion of the C-terminal transmembrane398 Immunity 30, 397–407, March 20, 2009 ª2009 Elsevier Inc.domain of RNF5 abolished its interaction with MITA, whereas the
C-terminal transmembrane domain containing fragment inter-
acted with MITA (Figures 1A and 1B). These results suggest
that the C-terminal transmembrane domain of RNF5 is required
for its interaction with MITA.
Previously, studies suggest that MITA is a multiple transmem-
brane domain-containing protein and the third transmembrane
domain of MITA (aa 111–150) is important for its mitochondrial
localization (Zhong et al., 2008). Deletion mutagenesis indicated
that this domain of MITA was also required for its interaction with
RNF5 (Figures 1A and 1C). These results suggest that MITA and
RNF5 interact through their respective transmembrane domains
that are also required for their membrane localization.
We next determined whether MITA interacts with RNF5 in
untransfected cells and the effects of viral infection on the
interaction. Endogenous coimmunoprecipitation experiments
indicated that MITA did not interact with RNF5 without stimula-
tion but was associated with RNF5 after viral infection
(Figure 1D). These results suggest that MITA is associated with
RNF5 in a viral-infection-dependent manner.
We also performed coimmunoprecipitation experiments to
examine whether RNF5 interacts with other molecules involved
in virus-induced type I IFN signaling. As shown in Figure S1
(available online), RNF5 interacted with RIG-I, VISA, TRADD,
and TRAF3 but not FADD, RIP, TRAF6, TBK1, and IRF3. Interest-
ingly, MITA is found to be associated with TRAF3 and VISA
but not RIP or TRAF6 (Zhong et al., 2008), and such a result is
consistent with a physical interaction between MITA and RNF5.
Overexpression of RNF5 Inhibits SeV-InducedActivation
of ISRE, NF-kB, and the IFN-b Promoter
Because RNF5 interacted with MITA in a viral-infection-depen-
dent manner, we determined whether RNF5 is involved in virus-
induced type I IFN signaling. Reporter assays indicated that
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Figure 2. RNF5 Inhibits SeV-Triggered
Signaling
(A) RNF5 inhibits SeV-induced activation of the
IFN-b promoter in a dose-dependent manner.
293 cells (1 3 105) were transfected with an IFN-b
promoter reporter (0.1 mg) and an increased
amount of RNF5 expression plasmid. Twenty
hours after transfection, cells were infected with
SeV or left untreated. Luciferase assays were
performed 12 hr after infection.
(B) Effects of RNF5 and RNF5 (C42S) on virus-
induced IFN-b promoter activation. 293 cells
(13 105) were transfected with an IFN-b promoter
reporter (0.1 mg) and the indicated expression
(0.1 mg each) plasmids. Twenty hours after trans-
fection, cells were infected with SeV or left
untreated. Luciferase assays were performed
12 hr after infection.
(C) RNF5 inhibits SeV-induced expression of
endogenous IFNB1, CCL5, and IFIT1. 293 cells
(2 3 105) were transfected with the indicated
expression plasmids (1 mg each) for 20 hr. The cells
were left untreated or infected with SeV for 10 hr
before RT-PCR for the indicated genes was
performed.
(D and E) RNF5 inhibits SeV-induced activation of
IFN-b promoter in human primary macrophages
(Mf) and dendritic cells (DCs).
(D) Monocyte-derived Mf (5 3 105) and (E) DCs
(1 3 106) were nucleofected with the indicated
plasmids (1.5 mg each). Twenty-four hours after
transfection, cells were left untreated or infected
with SeV for 16 hr before reporter assays were
performed.
(F) RNF5 inhibits SeV-induced ISRE activation. Experiments were performed similarly as in (B) except that an ISRE reporter was used.
(G) RNF5 inhibits SeV-induced IRF3 dimerization. 293 cells (2 3 105) were transfected with the indicated plasmids. Twenty hours after transfection, cells were
infected with SeV or left uninfected for 6 hr. Cell lysates were separated by native (upper panel) or SDS (bottom two panels) PAGE and analyzed by immunoblot-
ting with the indicated antibodies.
(H) RNF5 inhibits SeV-induced NF-kB activation. Experiments were performed similarly as in (B) except that an NF-kB reporter was used.
(I) RNF5 inhibits cytoplasmic dsRNA- and B-DNA-induced activation of the IFN-b promoter. 293 cells (13 105) were transfected with an IFN-b promoter reporter
(0.1 mg) and the indicated expression plasmids (0.1 mg each). Twenty hours after transfection, cells were further transfected with poly(I:C) (1 mg) or B-DNA (1 mg) for
12 hr before luciferase assays were performed.
For (C) and (G), experiments were performed for three times with similar results. For (A) and (B), (D)–(F), and (H) and (I), graphs show mean ± SD, n = 3.RNF5 inhibited SeV-induced activation of the IFN-b promoter in
a dose-dependent manner in 293 cells (Figure 2A). A catalytic
inactive mutant of RNF5, RNF5(C42S) (Younger et al., 2006), in
which the Cys42 in the ring-finger domain is mutated to serine,
lost its ability to inhibit SeV-induced activation of the IFN-b
promoter in both 293 (Figure 2B) and HeLa (Figure S2) cells.
Consistently, wild-type but not the C42S mutant RNF5 markedly
inhibited SeV-induced expression of endogenous IFNB1 and the
downstream genes CCL5 and IFIT1 in 293 cells (Figure 2C).
We further examined whether RNF5 regulates virus-induced
IFN-b expression in primary human macrophages and dendritic
cells (DCs). We isolated CD14+ monocytes and generated
monocyte-derived macrophages and DCs according to stan-
dard procedures. Reporter assays indicated that wild-type
RNF5 but not RNF(C42S) markedly inhibited SeV-induced acti-
vation of IFN-b promoter both in macrophages and DCs. In these
experiments, A20, which has previously shown to negatively
regulate virus-induced signaling (Lin et al., 2006b; Saitoh et al.,
2005; Wang et al., 2004), also inhibited SeV-induced activation
of IFN-b promoter (Figures 2D and 2E). These results suggestthat RNF5 inhibits virus-triggered signaling in primary human
immune cells.
Transcription induction of the IFNB1 gene requires coopera-
tive assembly of an enhanceosome containing both IRF3 and
NF-kB (Maniatis et al., 1998). Because RNF5 inhibited virus-
induced activation of the IFN-b promoter, we determined
whether RNF5 inhibits virus-induced activation of IRF3 and
NF-kB. The results indicated that wild-type RNF5 but not its
C42S mutant markedly inhibited SeV-induced ISRE activation
(Figure 2F), IRF3 dimerization (Figure 2G), and NF-kB activation
(Figure 2H). These results suggest that RNF5 inhibits virus-
induced activation of both IRF3 and NF-kB.
Previous studies demonstrate that MITA is also involved in
cytoplasmic poly(I:C)- and B-DNA-induced type I IFN signaling
(Ishikawa and Barber, 2008; Zhong et al., 2008). Consistent
with a role for RNF5 in regulating MITA, wild-type RNF5 but
not its C42S mutant inhibited poly(I:C)- and B-DNA-induced
activation of the IFN-b promoter in reporter assays (Figure 2I).
In similar experiments, RNF5 did not inhibit TNF-induced
NF-kB activation (Figure S3), suggesting that RNF5 specificallyImmunity 30, 397–407, March 20, 2009 ª2009 Elsevier Inc. 399
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Figure 3. Effects of RNAi-Mediated Knock-
down of RNF5 on SeV-Induced Signaling
(A) Effects of RNF5 RNAi plasmids on expression
of RNF5. In the upper panel, 293 cells (2 3 105)
were transfected with the indicated expression
plasmids (0.1 mg each) and RNAi plasmids (1 mg).
At 24 hr after transfection, cell lysates were
analyzed by immunoblotting with anti-Flag. In the
bottom panels, 293 cells (2 3 105) were trans-
fected with control or RNF5 RNAi plasmids (1 mg
each) for 24 hr. Cell lysates were analyzed by
immunoblotting with the indicated antibodies.
(B) Effects of RNF5 RNAi on SeV-induced activa-
tion of the IFN-b promoter in 293 cells. 293 cells
(1 3 105) were transfected with the indicated
amount of RNAi plasmids. An empty vector was
added to ensure that each transfection received
the same amount of total DNA. Twenty-four hours
after transfection, cells were left uninfected or
infected with SeV for 10 hr before luciferase assays
were performed. Immunoblot analysis was carried
out so that the expression level of RNF5 and
b-actin (lower panels) could be examined.
(C) Effects of RNF5 RNAi on SeV-induced expres-
sion of downstream genes. 293 cells (23 105) were
transfected with a control or RNF5 RNAi plasmid
(#2) (1 mg). Twenty-four hours after transfection,
cells were left uninfected or infected with SeV for
10 hr before RT-PCR was performed.
(D) Effects of RNF5 RNAi on SeV-induced ISRE
activation in 293 cells. 293 cells (1 3 105) were
transfected with a control or the indicated RNF5
RNAi plasmids (0.5 mg). Twenty-four hours after
transfection, cells were left untreated or infected
with SeV for 10 hr before reporter assays were
performed.
(E and F) Effects of RNF5 RNAi on SeV-induced
activation of the IFN-b promoter in human primary Mf and DCs. Monocyte-derived Mf (53 105, shown in [E]) and DCs (13 106, shown in [F]) were nucleofected
with the indicated plasmids (1.5 mg each). Twenty-four hours after transfection, cells were left untreated or infected with SeV for 16 hr before reporter assays were
performed.
(G) Effects of RNF5 RNAi on cytoplasmic dsRNA- and B-DNA-induced activation of the IFN-b promoter in 293 cells. 293 cells (1 3 105) were transfected with
a control or RNF5 RNAi plasmid (#2) (0.5 mg). Twenty-four hours after transfection, cells were further transfected with poly(I:C) (1 mg) or B-DNA (1 mg) or left un-
infected for 10 hr before luciferase assays were performed.
(H) Effects of RNF5 RNAi on TNF-induced NF-kB activation in 293 cells. Reporter assays were performed similarly as in (D) except that TNF (50 ng/ml) was used.
All experiments were repeated for at least three times with similar results. The bar graphs show mean ± SD, n = 3.inhibits signaling leading to induction of IFN-b and that this
inhibitory function requires its E3 ubiquitin ligase activity.
Knockdown of RNF5 Potentiates SeV-Induced
Activation of the IFN-b Promoter
Because overexpression of RNF5 inhibited virus-induced activa-
tion of IRF3, NF-kB, and the IFN-b promoter, we next determined
whether endogenous RNF5 regulates virus-induced signaling in
untransfected cells. To do this, we constructed three human
RNF5 RNAi plasmids. Two of these RNAi plasmids could mark-
edly inhibit the expression of transfected and endogenous RNF5
in 293 cells as suggested by immunoblot analysis (Figure 3A). In
reporter assays, these two RNF5 RNAi plasmids potentiated
SeV-induced activation of the IFN-b promoter in a dose-depen-
dent manner in 293 cells (Figure 3B). Knockdown of RNF5 also
potentiated SeV-induced transcription of endogenous IFNB1,
CCL5, and IFIT1 genes (Figure 3C) as well as activation of
ISRE (Figure 3D). We also determined whether endogenous
RNF5 is involved in regulation of virus-induced signaling other400 Immunity 30, 397–407, March 20, 2009 ª2009 Elsevier Inc.cell types. We found that RNF5 RNAi potentiated SeV-induced
IFN-b promoter activation in HeLa cells (Figure S4). More
importantly, knockdown of VISA and MITA markedly inhibited
SeV-induced IFN-b promoter activation, whereas knockdown
of RNF5 potentiated SeV-induced IFN-b promoter activation in
human primary macrophages (Figure 3E) and DCs (Figure 3F).
These observations suggest that the regulatory function of
RNF5 on virus-induced type I IFN signaling is not cell specific.
Similarly, we found that knockdown of RNF5 potentiated cyto-
plasmic dsRNA- and B-DNA-induced activation of the IFN-b
promoter (Figure 3G) but not TNF-induced NF-kB activation
(Figure 3H). These results suggest that RNF5 is a specific
physiological inhibitor of virus-triggered IRF3 activation and
IFN-b induction in various cell types.
RNF5 Regulates Virus-Induced Signaling at the MITA
Level
Because RNF5 was associated with MITA after viral infection
and acted as an inhibitor of virus-triggered signaling, we
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assays, RNF5 inhibited activation induced by MITA as well as
by its upstream components RIG-I and VISA, but RNF5 did not
inhibit ISRE activation induced by its downstream components
TBK1 and IRF3 (Figure 4A). Conversely, knockdown of RNF5
had opposite effects (Figure 4B). Similarly, RNF5 inhibited
VISA- but not TBK1-induced activation of NF-kB (Figure 4C)
and the IFN-b promoter (Figure 4D). These results suggest that
RNF5 negatively regulates virus-triggered signaling at the MITA
level.
RNF5 Targets MITA for Ubiquitination and Degradation
Because RNF5 is an E3 ubiquitin ligase and its enzymatic activity
is critical for inhibition of virus-induced signaling, we determined
whether RNF5 could ubiquitinate MITA. As shown in Figures 5A
and 5B, wild-type RNF5 but not RNF5(C42S) caused ubiquitina-
tion and downregulation of MITA. Because MITA-RNF5 interac-
tion was viral infection dependent in untransfected cells, we
determined whether viral infection caused ubiquitination of
endogenous MITA. The results indicated that endogenous
MITA was ubiquitinated and downregulated after SeV infection
(Figure 5C). Moreover, SeV-induced MITA ubiquitination and
downregulation were reversed by RNAi-mediated knockdown
of RNF5 (Figure 5C), whereas the proteasome inhibitor MG132
could reverse SeV-induced downregulation of endogenous
MITA as well as RNF5-mediated downregulation of overex-
pressed MITA (Figure S5). These results suggest that RNF5
targets MITA for ubiquitination and degradation after viral
infection through a proteasome-dependent pathway.
A C
B D
Figure 4. RNF5 Regulates Virus-Induced
Signaling at the MITA Level
(A) RNF5 inhibits RIG-I-, VISA-, and MITA- but
not TBK1- and IRF3-mediated ISRE activation.
293 cells (1 3 105) were transfected with the
indicatedl plasmids (0.2 mg each) together with
an ISRE reporter plasmid (0.1 mg). Reporter assays
were performed 20 hr after transfection.
(B) Knockdown of RNF5 enhances RIG-I-, VISA-,
and MITA- but not TBK1- and IRF3-mediated
ISRE activation. 293 cells (1 3 105) were trans-
fected with a control or RNF5-RNAi plasmid (#2)
(0.5 mg). Twelve hours later, cells were selected
with puromycin (1 mg/ml) for 24 hr and further
transfected with the indicated plasmids (0.1 mg
each) for 20 hr before reporter assays were per-
formed.
(C) RNF5 inhibits VISA- but not TBK1-mediated
activation of the IFN-b promoter. The experiments
were similarly performed as in (A).
(D) RNF5 inhibits VISA- not TBK1-mediated NF-kB
activation. The experiments were similarly per-
formed as in (A).
Graphs show mean ± SD, n = 3.
Because proteasomes normally recog-
nize and degrade proteins modified with
K48-linked polyubiquitin chains, we dete-
rmined whether RNF5 catalyzes K48- or
K63-linked ubiquitination of MITA. We
made expression plasmids for ubiquitin mutants retaining only
one single lysine residue, K48 (ubiquitin-K48) or K63 (ubiquitin-
K63). As shown in Figure 5D, immunoprecipitation and immuno-
blot analysis indicated that RNF5 catalyzed MITA ubiquitination
with wild-type ubiquitin and ubiquitin-K48 but not with ubiqui-
tin-K63, whereas TRAF6 caused IRF7 ubiquitination with wild-
type ubiquitin and ubiquitin-K63 but not ubiquitin-K48; such
a finding is consistent with a previous report that TRAF6 catalyzes
K63-linked ubiquitination of IRF7 (Ning et al., 2008). Consistently,
RNF5-catalyzed ubiquitination of MITA was detected with an
antiubiquitin but not with an anti-K63-linked polyubiquitin anti-
body, whereas TRAF6-mediated ubiquitination of IRF7 was
detected with both antibodies (Figure 5E). Taken together, these
data suggest that RNF5 catalyzes K48-linked ubiquitination of
MITA, which is recognized and degraded by the proteasome
system.
During our coimmunoprecipitation experiments, we routinely
observed that RNF5 caused shifts of MITA(1-160) to higher
molecular bands (Figure 1C), suggesting the possibility that the
ubiquitination site of MITA is located in this region. Sequence
analysis identified three lysine residues in this region, which
are K20, K137, and K150. We mutated these lysine residues
into arginines individually and found that mutation of K150
to arginine abolished RNF5-mediated MITA ubiquitination
(Figure 5F). Consistently, RNF5 caused degradation of wild-
type but not K150R mutant MITA (Figures 5F and Figure S6).
In reporter assays, MITA(K150R) could induce ISRE activation
to a higher level than its wild-type counterpart. In addition,
MITA(K150R)-induced ISRE activation was markedly more resis-
tant to the inhibitory effect of RNF5 (Figure 5G). These results
Immunity 30, 397–407, March 20, 2009 ª2009 Elsevier Inc. 401
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Figure 5. RNF5 Targets MITA for Ubiquinta-
tion and Degradation
(A) Overexpression of wild-type but not mutant
RNF5 promotes ubiquitination of MITA. 293 cells
(1 3 107) were transfected with the indicated
plasmids. Twenty hours after transfection, cell
lysates were immunoprecipitated with anti-MITA.
The immunoprecipitates were denatured and
reimmunoprecipitated with anti-MITA and then
analyzed by immunoblotting with antiubiquitin
(upper panel). The expression levels of the proteins
were examined by immunoblotting with the indi-
cated antibodies (lower panels).
(B) Overexpression of RNF5 caused downregula-
tion of MITA. 293 cells (2 3 105) were transfected
with the indicated plasmids. Twenty-four hours
after transfection, cells were lysed for immunoblot
analysis with anti-Flag (upper panel) or anti-HA
(lower panel).
(C) Effects of RNF5 RNAi on SeV-induced ubiquiti-
nation of endogenous MITA. 293 cells (5 3 107)
were transfected with a control or the RNF5 RNAi
plasmid (#2). Twenty-four hours after transfection,
cells were infected with SeV or left untreated for
6 hr. The cell lysates were immunoprecipitated
with anti-MITA. The immunoprecipitates were
denatured and reimmunoprecipitated with anti-
MITA and then analyzed by immunoblotting with
antiubiquitin (upper panel). The expression of the
related proteins was examined by immunoblotting
with the indicated antibodies (lower panels).
(D) RNF5 catalyzes K48-linked ubiquitination of
MITA, whereas TRAF6 catalyzes K63-linked ubiquitination of IRF7. 293 cells (2 3 106) were transfected with the indicated plasmids. Twenty hours after trans-
fection, immunoprecipitation, reimmunoprecipitation and immunoblot analysis were performed with the indicated antibodies (upper panels). The expression of
the proteins was examined by immunoblotting with the indicated antibodies (lower panels).
(E) RNF5-mediated ubiquitination of MITA is not detected by a K63-linkage specific ubiquitin antibody. 293 cells (2 3 106) were transfected with the indicated
plasmids. Twenty hours after transfection, immunoprecipitation, reimmunoprecipitation and immunoblot analysis were performed with the indicated antibodies
(upper two panels). The expression of the transfected proteins was examined by immunoblotting with the indicated antibodies (lower panels).
(F) Mapping of RNF5-targeted ubiquitination sites of MITA. 293 cells (23 106) were transfected with the indicated plasmids. Twenty-four hours after transfection,
the cell lysates were immunoprecipitated with anti-Flag. The immunoprecipitates were denatured and reimmunoprecipitated with anti-Flag and then analyzed by
immunoblotting with antiubiquitin (upper panel). The expression of the tranfected proteins was examined by immunoblotting with the indicated antibodies (lower
panels).
(G) Effects of RNF5 on wild-type and K150R mutant MITA-mediated ISRE activation. 293 cells (13 105) were transfected with the indicated plasmids. Luciferase
assays were performed 24 hr after transfection. Graphs show mean ± SD, n = 3.
For (A)–(F), experiments were repeated for three times with similar results.suggest that RNF5 targets MITA at K150 for ubiquitination and
this modification is important for RNF5-mediated negative
regulation of virus-induced signaling.
RNF5 Interacts with and Ubiquitinates MITA
at the Mitochondria
Having established that RNF5 negatively regulates virus-
triggered signaling by targeting MITA for ubiquitination and
degradation, we next examined whether viral infection affects
expression of MITA and RNF5 in a temporal manner. We found
that the total amount of cellular MITA was noticeably reduced
at 6 hr after SeV infection and then restored at 9 hr after SeV
infection. In contrast, the amount of cellular RNF5 was not
noticeably changed before and after viral infection (Figure 6A).
The reduction of MITA at 6 hr after viral infection was caused
by RNF5 because RNAi-mediated knockdown of this protein
abolished the effect (Figure 6A). These results further support
our conclusion that virus-induced MITA ubiquitination and
degradation is dependent on RNF5.402 Immunity 30, 397–407, March 20, 2009 ª2009 Elsevier Inc.It was reported that RNF5 is localized to the ER or endosome
(Younger et al., 2006; Zhang et al., 2005). Whether RNF5 is also
localized to the mitochondria was not examined in the previous
studies (Younger et al., 2006). Cell fractionation and confocal
microscopy experiments indicated that RNF5 was identified
both in the mitochondrion- and the ER-containing membrane
fractions in unstimulated cells (Figures 6B and 6C). Consistent
with previous reports (Jin et al., 2008; Zhong et al., 2008),
MITA was mostly found in the mitochondria in unstimulated
cells and barely detectable in the ER (Figure 6B). Confocal
microscopy experiments also indicated that a fraction of RNF5
colocalized with MITA at the mitochondria (Figure 6C). Interest-
ingly, infection of cells with SeV for 6 hr caused upregulation
of RNF5 and simultaneous downregulation of MITA in the mito-
chondria (Figure 6B). Noticeably, SeV also caused the upregula-
tion of MITA in the ER at 6 hr after infection (Figure 6B). We next
determined whether virus-induced ubiquitination of MITA by
RNF5 occurs in the mitochondria or the ER. We isolated the
mitochondria- and ER-containing membrane fractions and
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Figure 6. RNF5 Interacts with and Ubiquitinates MITA at the Mitochondria
(A) Effects of SeV infection on expression of MITA and RNF5. 293 cells (23 106) were transfected with a control or the RNF5-RNAi plasmid (#2). Twenty-four hours
later, cells were infected with SeV for the indicated time points followed by immunoblot analysis with the indicated antibodies.
(B) Effects of SeV infection on subcellular distribution of MITA and RNF5. 293 cells (13 107) were left untreated or infected with SeV for the indicated time points
and fractionated as shown in the diagram. The cellular fractions were analyzed by immunoblotting with the indicated antibodies.
(C) RNF5 and MITA colocalize to the mitochondria. 293 cells were transfected with CFP-RNF5 and YFP-MITA. Twenty hours after transfection, cells were stained
with the Mito Tracker Red (1 mM) for 30 min. The cells were fixed with 4% paraformaldehyde and subjected for confocal microscopy.
(D) RNF5 interacts with and ubiquitinates MITA at the mitochondria. 293 cells (1 3 108) were infected with SeV or left uninfected for 6 hr. Cell lysates were
fractionated as in (B). The fractions were lysed and the lysates were immunoprecipitated with anti-MITA; the immunoprecipitates were denatured and
reimmunoprecipitated with anti-MITA and analyzed by immunoblotting with antiubiquitin (upper panel). Alternatively, the lysates were immunoprecipitated
with anti-RNF5 and the immunoprecipitates were analyzed by immunoblotting with anti-MITA (middle panel). A fraction of lysate was taken for immunoblot
analysis to detect the expression levels of the indicated proteins (bottom four panels).
All experiments were repeated for three times with similar results.performed coimmunoprecipitation analysis. As shown in
Figure 6D, RNF5 interacted with and ubiquitinated MITA in the
mitochondrial but not the ER fraction at 6 hr after SeV infection.
These results suggest that RNF5 targets MITA for ubiquitination
and degradation in the mitochondria but not the ER after viral
infection.
RNF5 Inhibits MITA-Mediated Cellular Antiviral
Response
Because RNF5 targeted MITA for ubiquitination and degrada-
tion, and acted as an inhibitor for virus-induced activation
of IRF3, NF-kB, and the IFN-b promoter, we investigated
whether RNF5 regulates MITA-mediated cellular antiviral innate
immunity. In plaque assays, overexpression of wild-type but
not the C42S mutant RNF5 abolished MITA- and cytoplasmic
poly(I:C)-mediated inhibition of VSV production in both 293 andHeLa cells (Figure 7A). Conversely, knockdown of RNF5
enhanced the inhibitory effects on viral replication mediated by
MITA or triggered by cytoplasmic poly(I:C) (Figure 7B). These
results suggest that RNF5 is a suppressor of MITA-mediated
cellular antiviral response.
DISCUSSION
Previous studies have demonstrated that MITA plays an
essential role in virus-triggered induction of type I IFNs and
innate antiviral immunity (Ishikawa and Barber, 2008; Zhong
et al., 2008). However, how its activities are regulated is
unknown. We performed yeast two-hybrid screens and identi-
fied RNF5 as a MITA-interacting protein. Although RNF5 inter-
acted with MITA constitutively in overexpression system, their
association was viral infection dependent in untransfected cells.Immunity 30, 397–407, March 20, 2009 ª2009 Elsevier Inc. 403
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brane domains required for their respective membrane localiza-
tion were also required for their interaction. Previous studies
have demonstrated that RNF5 is an E3 ubiquitin ligase (Matsuda
et al., 2001; Younger et al., 2006; Zhang et al., 2005). Corre-
spondingly, overexpression of wild-type RNF5 but not its
enzymatic inactive mutant caused ubiquitination and degrada-
tion of MITA. Site-directed mutagenesis indicated that RNF5
ubiquitinated MITA at K150. Moreover, viral infection caused
ubiquitination and degradation of endogenous MITA by RNF5,
as evidenced by the observation that RNAi-mediated knock-
down of RNF5 diminished these effects. Further experiments
indicate that RNF5 catalyzed K48-linked ubiquitination of
MITA, and SeV-induced or RNF5-mediated downregulation
of MITA was reversed by addition of the proteasome inhibitor
MG132. These results suggest that RNF5 targets MITA for
K48-linked ubiquitination and degradation by the proteasome
pathway. Consistent with these observations, overexpression
of wild-type but not enzymatic inactive mutant RNF5 inhibited
SeV-induced activation of IRF3, NF-kB, and the IFN-b promoter
as well as endogenous expression of IFNB1, whereas knock-
down of RNF5 had the opposite effects in various types of cells
including primary human macrophages and DCs. In plaque
assays, overexpression of RNF5 inhibited MITA-mediated
cellular antiviral response, whereas knockdown of RNF5 poten-
tiated MITA-mediated inhibition of viral replication. These
observations collectively suggest that RNF5 acts as a negative
regulator of virus-induced type I IFN expression and cellular
A
B
Figure 7. Roles of RNF5 in Cellular Antiviral Response
(A) Overexpression of wild-type but not the C42S mutant RNF5 increases VSV
replication. 293 (left) or HeLa (right) cells (1 3 105) were transfected with the
indicated expression plasmids (0.5 mg each). For 293 cells (left), 24 hr later,
transfection cells were further transfected with poly(I:C) or left untransfected
for 12 hr before cells were infected with VSV (MOI = 0.01). The supernatants
were harvested 24 hr after infection for standard plaque assays. Graphs
show mean ± SD, n = 3.
(B) Knockdown of RNF5 inhibits VSV replication. Plaque assays were
performed as in (A) except that a control or RNF5 RNAi plasmid (#2) (1 mg)
was transfected and VSV at MOI of 0.1 were used for infection. Graphs
show mean ± SD, n = 3. (**p < 0.01; *p < 0.05).404 Immunity 30, 397–407, March 20, 2009 ª2009 Elsevier Inc.antiviral response by targeting MITA for ubiquitination and
degradation.
Signaling triggered by viral infection occurs promptly. Previ-
ously, we demonstrate that MITA recruits TBK1 and IRF3 to
the mitochondrion-bound VISA complex at 2 hr after viral infec-
tion (Zhong et al., 2008). However, the ‘‘activated’’ state of host
cells needs to be timely terminated to avoid autoimmune
diseases. Consistently, we found that MITA was ubiquitinated
and degraded at 6 hr after viral infection. In this context, it is
observed that IRF3 undergoes ubiquitination and degradation
at 4–6 hr after viral infection (Bibeau-Poirier et al., 2006).
Although previous studies demonstrated that RNF5 is located
at the ER (Younger et al., 2006), our cell fractionation experiments
also identified similar amount of RNF5 in the mitochondria. In
unstimulated cells, RNF5 did not interact with MITA, even though
both proteins were present at the mitochondria. After viral infec-
tion, RNF5 interacted with MITA at the mitochondria, where it
ubiquitinated and degraded MITA. It is possible that viral infection
causes a dynamic recruitment of RNF5 to MITA, though the exact
mechanism is unknown. Although both MITA and RNF5 were
found in the ER after viral infection, the ER-associated MITA
was not detected to be associated with and ubiquitinated by
RNF5. Our results suggest that RNF5-mediated ubiquitination
and degradation of MITA after viral infection occur at the
mitochondria, and such a finding is consistent with previous
observations that VISA is located at the mitochondria and
required for virus-induced type I IFN expression (Seth et al.,
2005). In this study, we found that after viral infection, the amount
of RNF5 was noticeably decreased in the ER and increased in the
mitochondria, whereas the amount of MITA had an opposite shift.
The simplest explanation for these observations is that viral infec-
tion induces translocation of a fraction of RNF5 from the ER to the
mitochondria, resulting in increased ubiquitination and degrada-
tion of MITA at the mitochondria after viral infection. In this
context, it has been extensively shown that 20% mitochondrial
membrane is positioned against the ER and various molecules,
including lipid, ions, cellular and viral proteins, are translocated
from the ER to the mitochondria continually or under certain
conditions (Franzini-Armstrong, 2007).
The functional significance of virus-induced increase of
MITA in the ER is unknown at this time. It has been reported by
various groups that IRF3 was activated 4–6 hr after SeV infection
(Bibeau-Poirier et al., 2006), which proceeds the increase of
ER-associated MITA. In addition, previous studies have demon-
strated that MITA is required for signaling by the RLR adaptor
protein VISA, which has been demonstrated by several groups
to be a mitochondrial protein (Ishikawa and Barber, 2008; Lin
et al., 2006a; Seth et al., 2005; Zhong et al., 2008). Therefore,
it is less possible that the increase of ER-associated MITA
is more relevant to RLR signaling. Previous studies have demon-
strated that MITA is also required for cytoplasmic poly(I:C)- and
B-DNA-induced type I IFN signaling (Ishikawa and Barber, 2008;
Zhong et al., 2008). Consistently, we found that RNF5 negatively
regulated cytoplasmic poly(I:C)- and B-DNA-induced signaling.
These observations further support our conclusion that RNF5
is a negative regulator of MITA-mediated signaling.
Available studies suggest that host cells adopt at least two
distinct mechanisms to control excessive antiviral innate
immune response. First, some inhibitory proteins, such as
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components of virus-induced type I IFN signaling pathways to
sequester them in inactive forms. Viral infection leads to release
of these inhibitors and activation of the signaling components
(Diao et al., 2007; Huang et al., 2005; Moore et al., 2008). The
second mechanism involves the ubiquitin-proteosome system.
Several members of the E3 ubiquitin ligase family, such as
RNF125, Pin1, RBCK1, and Rho52, target the key components
of the virus-induced type I IFN signaling pathways for degrada-
tion (Arimoto et al., 2007; Higgs et al., 2008; Saitoh et al., 2006;
Zhang et al., 2008). The discovery that RNF5 targets MITA for
ubiquitination and degradation in the mitochondria provides
new insight into the mechanism responsible for control of exces-
sive cellular antiviral response.
EXPERIMENTAL PROCEDURES
Reagents
TNF (R&D Systems), mouse monoclonal antibodies against Flag, HA and
b-actin (Sigma), AIF, and KDEL (Santa Cruz Biotechnology), K63-linkage
specific polyubiquitin chain (Biomol), and rabbit polyclonal antibodies against
IRF3 and IRF7 (Santa Cruz Biotechnology) were purchased from the indicated
manufacturers. SeV, VSV, and rabbit and mouse MITA antibodies were previ-
ously described (Zhong et al., 2008). Mouse anti-RNF5 antiserum were raised
against recombinant human RNF5(1168).
Constructs
NF-kB, ISRE, and the IFN-b promoter luciferase reporter plasmids and
mammalian expression plasmids for HA- or Flag-tagged MITA and its mutants,
RIG-I, TBK1, RIP, TRAF6, TRAF3, and TRADD were previously described (Diao
et al., 2007; Huang et al., 2005; Xu et al., 2005; Zhong et al., 2008). Mammalian
expression plasmids for human HA-, Flag-, or CFP-tagged RNF5 and its trun-
cated mutants were constructed by standard molecular biology techniques.
The RNF5(C42S) was a generous gift from D. Cyr (University of North Carolina).
Yeast Two-Hybrid Screens, Transfection and Reporter Assays,
RT-PCR, Coimmunoprecipitation, Immunoblot Analysis, Native
PAGE and VSV Plaque Assay
These experiments were performed as described (Diao et al., 2007; Huang
et al., 2005; Xu et al., 2005; Zhong et al., 2008).
Reimmunoprecipitation Experiments
First-round immunoprecipitation was performed as described (Diao et al.,
2007; Huang et al., 2005; Xu et al., 2005; Zhong et al., 2008). The immunopre-
cipitates were re-extracted in lysis buffer containing 1% SDS and denatured
by heating for 5 min. The supernatants were diluted with regular lysis buffer
until the concentration of SDS was decreased to 0.1%. The diluted superna-
tants were reimmunoprecipitated with the indicated antibodies, and the
immunoprecipitates were analyzed by immunoblotting with the ubiquitin
antibody.
Generation and Transfection of Human Primary Macrophages
and Dendritic Cells
Peripheral blood monocytes (PBMCs) were isolated from healthy human
peripheral blood by density gradient separation with Ficoll-Paque (GE Health-
care) in accordance with the manufacturer’s instructions. The isolated PBMCs
were incubated with human CD14-specific antibody conjugated to paramag-
netic microbeads (Miltenyi Biotec), and the CD14+ monocytes were isolated on
the LS columns (Miltenyi Biotec). The monocytes were suspended in RPMI
1640 supplemented with 10% heat-inactivated FBS (ExCell), 1% nonessential
amino acids, and 1 mM sodium pyruvate. For generation of macrophages and
DCs, the CD14+ monocytes were treated with either recombinant human (rh)
M-CSF (50 ng/ml) or rhGM-CSF (50 ng/ml) and rhIL-4 (100 ng/ml) (PeproTech)
for 6 days. The media with the cytokines were changed every other day during
the differentiation period. Differentiated macrophages and dendritic cells wereharvested and transfected with the human macrophage or dendritic cell nucle-
ofactor kit (Amaxa). Immediately after transfection, cells were resuspended in
the cytokine-containing media. Twenty-four hours after transfection, cells
were infected with SeV for 16 hr before reporter assays were performed.
RNAi
Double-strand oligonucleotides corresponding to the target sequences were
cloned into the pSuper.Retro RNAi plasmid (Oligoengine). The following
sequenceswere targeted forhuman RNF5 cDNA:RNF5-RNAi#1:50-gcgcgacctt
cgaatgtaa-30; #2: 50-cggcaagagtgtccagtat-30; #3: 50-gggaagctgtggtcagtgt-30.
Subcellular Fractionation
The cell fractionation experiments were performed as previously described
(Zhong et al., 2008). In brief, 293 cells (1 3 107) infected with SeV or left unin-
fected for various time points were washed with PBS and lysed by douncing for
40 times in 2 ml homogenization buffer (10 mM Tris-HCl [pH 7.4], 2 mM MgCl2,
10 mM KCl, and 250 mM Sucrose). The homogenate was twice centrifuged at
500 g for 10 min, and the pellet (P5) was saved as crude nuclei. The superna-
tant (S5) was centrifuged at 5,000 g for 10 min for crude mitochondria (P5K)
precipitation. The supernatant (S5K) was further centrifuged at 50,000 g for
60 min for S50K and P50K generation. The fractions of P5K and P50K were
lysed in lysis buffer (20 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1 mM EDTA,
and 1% NP-40, protease inhibitor cocktail) for 20 min; this was followed by
immunoprecipitation or immunoblot analysis.
SUPPLEMENTAL DATA
Supplemental Data include six figures and can be found with this article online
at http://www.immunity.com/supplemental/S1074-7613(09)00106-X.
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